Evidence map›Paper›PMID 33584655›Full record

ArticleFrontiers in immunology2020

Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-

Vera Buchele, Patrick Konein, Tina Vogler, Timo Kunert, Karin Enderle, Hanif Khan, Maike Büttner-Herold, Christian H K Lehmann, Lukas Amon, Stefan Wirtz and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. ProbioticAntioxidants (Basel, Switzerland) · 2025
    Article
  5. Review
  6. TIME for Bugs: The Immune Microenvironment and Microbes in Precancer.Cancer prevention research (Philadelphia, Pa.) · 2023
    Review
  7. Molecules (Basel, Switzerland) · 2023
    Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Vera BucheleDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Patrick KoneinDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Tina VoglerDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Timo KunertDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Karin EnderleDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Hanif KhanDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Maike Büttner-HeroldInstitute of Pathology, Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany.
Christian H K LehmannDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Lukas AmonDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Stefan WirtzDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Diana DudziakDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Markus F NeurathDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Clemens NeufertDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Kai HildnerDepartment of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Universitätsklinikum Erlangen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBDs) are characterized by chronic, inflammatory gastrointestinal lesions and often require life-long treatment with immunosuppressants and repetitive surgical interventions. Despite progress in respect to the characterization of molecular mechanisms

Indexed as

AnimalsColitisColonHomeodomain ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsMiceMice, Inbred C57BLMice, TransgenicT-LymphocytesHomeodomain ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsRAG-1 proteininflammatory bowel disease (IBD)interferon regulatory factor 4 (IRF4)intestinal inflammationmyeloid cellsTh17

Identifiers

PMID33584655
PMCPMC7879684
OpenAlexW3127057655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.